Home Mercks KEYTRUDA (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
 

Keywords :   


Mercks KEYTRUDA (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1

2015-10-26 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline results from the KEYNOTE-010 study of KEYTRUDA (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced shows express cell

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11contactglove tundratracker
23.11
23.11RUSSELUNO
23.11C282 800yd IP54
23.11X-FLY4 27.5
23.118
23.11 (1~40)
23.1101DVDBOX
More »